| scholarly article | Q13442814 |
| P2093 | author name string | Xiaoli Ma | |
| Dongjie Xiao | |||
| Yanfei Jia | |||
| Yunshan Wang | |||
| Duanrui Liu | |||
| P2860 | cites work | Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement | Q21195843 |
| Memory Rehabilitation for people with multiple sclerosis | Q24201168 | ||
| Molecular-targeted first-line therapy for advanced gastric cancer | Q26471049 | ||
| Apatinib for molecular targeted therapy in tumor | Q26775828 | ||
| Operating characteristics of a rank correlation test for publication bias | Q27860653 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis | Q28079362 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program | Q30313895 | ||
| Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity | Q31153818 | ||
| Phase II study of sunitinib as second-line treatment for advanced gastric cancer | Q33389519 | ||
| Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study | Q33410627 | ||
| Molecular targeting to treat gastric cancer | Q34326593 | ||
| Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management | Q34434066 | ||
| An overview of small-molecule inhibitors of VEGFR signaling | Q34611616 | ||
| Ramucirumab: successfully targeting angiogenesis in gastric cancer. | Q34616558 | ||
| Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q34645665 | ||
| Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl | Q34669325 | ||
| Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice | Q34671886 | ||
| Adverse effects of anticancer agents that target the VEGF pathway | Q34990961 | ||
| Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction | Q35208151 | ||
| Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review | Q35584543 | ||
| Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies | Q36137701 | ||
| Anti-angiogenic treatment of gastrointestinal malignancies | Q36353516 | ||
| Vascular endothelial growth factor signaling pathways: therapeutic perspective | Q36584934 | ||
| The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review | Q36650719 | ||
| Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials | Q38008738 | ||
| Emerging tyrosine kinase inhibitors for esophageal cancer | Q38110962 | ||
| Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial | Q38386171 | ||
| Angiogenesis inhibitors in gastric and gastroesophageal junction cancer | Q38578404 | ||
| Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials | Q38685279 | ||
| Targeted therapies in gastric cancer treatment: where we are and where we are going. | Q38731943 | ||
| Second-line chemotherapy for patients with advanced gastric cancer. | Q38750633 | ||
| Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis | Q38760954 | ||
| Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model | Q39160279 | ||
| Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction | Q39991776 | ||
| Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis | Q41709168 | ||
| Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward. | Q42336235 | ||
| FDA Approval Summary: Ramucirumab for Gastric Cancer. | Q53477556 | ||
| A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. | Q54526078 | ||
| An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer | Q84077312 | ||
| Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial | Q87206964 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8120-8132 | |
| P577 | publication date | 2017-12-19 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis. | |
| P478 | volume | 9 |
Search more.